nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabigatran etexilate—UGT2B7—Tamoxifen metabolism—CYP1B1—glaucoma	0.00376	0.0171	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Estrogen metabolism—CYP1B1—glaucoma	0.00345	0.0157	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Estrogen metabolism—GSTM1—glaucoma	0.0034	0.0155	CbGpPWpGaD
Dabigatran etexilate—CES2—NRF2 pathway—SLC6A1—glaucoma	0.00339	0.0155	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Phase II conjugation—GSTT1—glaucoma	0.00329	0.015	CbGpPWpGaD
Dabigatran etexilate—CES1—Fluoropyrimidine Activity—MTHFR—glaucoma	0.00322	0.0147	CbGpPWpGaD
Dabigatran etexilate—F2—Complement and Coagulation Cascades—C1QB—glaucoma	0.0032	0.0146	CbGpPWpGaD
Dabigatran etexilate—CES2—NRF2 pathway—TGFB2—glaucoma	0.00277	0.0126	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Estrogen metabolism—GSTM1—glaucoma	0.00276	0.0126	CbGpPWpGaD
Dabigatran etexilate—F2—Regulation of IGF Activity by IGFBP—MMP1—glaucoma	0.00274	0.0125	CbGpPWpGaD
Dabigatran etexilate—CES1—NRF2 pathway—SLC6A13—glaucoma	0.00273	0.0125	CbGpPWpGaD
Dabigatran etexilate—CES1—NRF2 pathway—TXN—glaucoma	0.00224	0.0102	CbGpPWpGaD
Dabigatran etexilate—F2—Regulation of IGF Activity by IGFBP—MMP2—glaucoma	0.00212	0.00966	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Phase II conjugation—GSTM1—glaucoma	0.0021	0.00956	CbGpPWpGaD
Dabigatran etexilate—CES2—Fluoropyrimidine Activity—TP53—glaucoma	0.00207	0.00945	CbGpPWpGaD
Dabigatran etexilate—F2—Selenium Micronutrient Network—TXN—glaucoma	0.00207	0.00945	CbGpPWpGaD
Dabigatran etexilate—F2—Post-translational protein modification—DHPS—glaucoma	0.00204	0.00931	CbGpPWpGaD
Dabigatran etexilate—CES1—NRF2 pathway—SLC6A1—glaucoma	0.002	0.00912	CbGpPWpGaD
Dabigatran etexilate—F2—Vitamin B12 Metabolism—ABCA1—glaucoma	0.00198	0.00903	CbGpPWpGaD
Dabigatran etexilate—CES2—E2F transcription factor network—CDKN2A—glaucoma	0.00197	0.009	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Biological oxidations—GSTT1—glaucoma	0.00192	0.00878	CbGpPWpGaD
Dabigatran etexilate—F2—G alpha (q) signalling events—OPN4—glaucoma	0.00189	0.00863	CbGpPWpGaD
Dabigatran etexilate—CES2—NRF2 pathway—GSTM1—glaucoma	0.00188	0.00857	CbGpPWpGaD
Dabigatran etexilate—F2—Syndecan-4-mediated signaling events—FN1—glaucoma	0.00178	0.00813	CbGpPWpGaD
Dabigatran etexilate—F2—Vitamin B12 Metabolism—SOD1—glaucoma	0.00176	0.00805	CbGpPWpGaD
Dabigatran etexilate—CES2—E2F transcription factor network—CDKN1B—glaucoma	0.00175	0.00797	CbGpPWpGaD
Dabigatran etexilate—F2—G alpha (q) signalling events—PTGFR—glaucoma	0.0017	0.00777	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—OPN4—glaucoma	0.00169	0.00772	CbGpPWpGaD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—MYLK—glaucoma	0.00169	0.00769	CbGpPWpGaD
Dabigatran etexilate—F2—FOXA2 and FOXA3 transcription factor networks—NR3C1—glaucoma	0.00165	0.00752	CbGpPWpGaD
Dabigatran etexilate—CES1—NRF2 pathway—TGFB2—glaucoma	0.00163	0.00743	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Aryl Hydrocarbon Receptor Pathway—CYP1B1—glaucoma	0.00163	0.00743	CbGpPWpGaD
Dabigatran etexilate—F2—Folate Metabolism—ABCA1—glaucoma	0.00161	0.00735	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet Aggregation (Plug Formation)—FN1—glaucoma	0.00159	0.00724	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—NRF2 pathway—SLC6A13—glaucoma	0.00157	0.00716	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Biological oxidations—CYP1B1—glaucoma	0.00153	0.00699	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—PTGFR—glaucoma	0.00152	0.00695	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Phase II conjugation—GSTT1—glaucoma	0.0015	0.00683	CbGpPWpGaD
Dabigatran etexilate—F2—Folate Metabolism—SOD1—glaucoma	0.00144	0.00655	CbGpPWpGaD
Dabigatran etexilate—F2—IL1 and megakaryotyces in obesity—MMP9—glaucoma	0.00143	0.00653	CbGpPWpGaD
Dabigatran etexilate—F2—Vitamin B12 Metabolism—MTHFR—glaucoma	0.0014	0.00638	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—NARFL—glaucoma	0.00135	0.00615	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—CA5A—glaucoma	0.00135	0.00615	CbGpPWpGaD
Dabigatran etexilate—F2—Vitamin B12 Metabolism—APOE—glaucoma	0.0013	0.00594	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—NRF2 pathway—TXN—glaucoma	0.00129	0.00588	CbGpPWpGaD
Dabigatran etexilate—F2—Selenium Micronutrient Network—ABCA1—glaucoma	0.00128	0.00584	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—NRF2 pathway—SLC6A13—glaucoma	0.00128	0.00582	CbGpPWpGaD
Dabigatran etexilate—F2—Post-translational protein modification—CTSA—glaucoma	0.00127	0.00581	CbGpPWpGaD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—OPN4—glaucoma	0.00125	0.00572	CbGpPWpGaD
Dabigatran etexilate—F2—Angiopoietin receptor Tie2-mediated signaling—FN1—glaucoma	0.00125	0.00569	CbGpPWpGaD
Dabigatran etexilate—F2—Complement and Coagulation Cascades—C3—glaucoma	0.00125	0.00568	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Biological oxidations—GSTM1—glaucoma	0.00123	0.00559	CbGpPWpGaD
Dabigatran etexilate—CES1—Fluoropyrimidine Activity—TP53—glaucoma	0.00122	0.00557	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Phase II conjugation—GSTT1—glaucoma	0.00122	0.00555	CbGpPWpGaD
Dabigatran etexilate—Nausea—Carbachol—glaucoma	0.00116	0.00149	CcSEcCtD
Dabigatran etexilate—CES1—E2F transcription factor network—CDKN2A—glaucoma	0.00116	0.00531	CbGpPWpGaD
Dabigatran etexilate—Infection—Travoprost—glaucoma	0.00116	0.00149	CcSEcCtD
Dabigatran etexilate—Headache—Methazolamide—glaucoma	0.00116	0.00148	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Clonidine—glaucoma	0.00116	0.00148	CcSEcCtD
Dabigatran etexilate—Chest pain—Pilocarpine—glaucoma	0.00116	0.00148	CcSEcCtD
Dabigatran etexilate—Arthralgia—Pilocarpine—glaucoma	0.00116	0.00148	CcSEcCtD
Dabigatran etexilate—Shock—Dorzolamide—glaucoma	0.00115	0.00148	CcSEcCtD
Dabigatran etexilate—UGT2B7—NRF2 pathway—SLC6A1—glaucoma	0.00115	0.00524	CbGpPWpGaD
Dabigatran etexilate—Hypotension—Brimonidine—glaucoma	0.00115	0.00147	CcSEcCtD
Dabigatran etexilate—Nausea—Levobunolol—glaucoma	0.00115	0.00147	CcSEcCtD
Dabigatran etexilate—Infection—Brinzolamide—glaucoma	0.00115	0.00147	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Travoprost—glaucoma	0.00115	0.00147	CcSEcCtD
Dabigatran etexilate—Nasopharyngitis—Timolol—glaucoma	0.00115	0.00147	CcSEcCtD
Dabigatran etexilate—F2—Selenium Micronutrient Network—SOD1—glaucoma	0.00114	0.0052	CbGpPWpGaD
Dabigatran etexilate—Epistaxis—Betaxolol—glaucoma	0.00114	0.00146	CcSEcCtD
Dabigatran etexilate—F2—Folate Metabolism—MTHFR—glaucoma	0.00114	0.00519	CbGpPWpGaD
Dabigatran etexilate—F2—Syndecan-4-mediated signaling events—MMP9—glaucoma	0.00114	0.00518	CbGpPWpGaD
Dabigatran etexilate—Skin disorder—Travoprost—glaucoma	0.00113	0.00145	CcSEcCtD
Dabigatran etexilate—Sinusitis—Betaxolol—glaucoma	0.00113	0.00145	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Apraclonidine—glaucoma	0.00113	0.00145	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Brinzolamide—glaucoma	0.00113	0.00145	CcSEcCtD
Dabigatran etexilate—Angiopathy—Clonidine—glaucoma	0.00113	0.00145	CcSEcCtD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—PTGFR—glaucoma	0.00113	0.00515	CbGpPWpGaD
Dabigatran etexilate—Rash—Latanoprost—glaucoma	0.00113	0.00144	CcSEcCtD
Dabigatran etexilate—Dermatitis—Latanoprost—glaucoma	0.00113	0.00144	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Acetazolamide—glaucoma	0.00113	0.00144	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Clonidine—glaucoma	0.00112	0.00144	CcSEcCtD
Dabigatran etexilate—Headache—Latanoprost—glaucoma	0.00112	0.00144	CcSEcCtD
Dabigatran etexilate—Skin disorder—Brinzolamide—glaucoma	0.00112	0.00143	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Brimonidine—glaucoma	0.00112	0.00143	CcSEcCtD
Dabigatran etexilate—F2—PAR1-mediated thrombin signaling events—NOS3—glaucoma	0.00112	0.0051	CbGpPWpGaD
Dabigatran etexilate—CES1—NRF2 pathway—GSTM1—glaucoma	0.00111	0.00505	CbGpPWpGaD
Dabigatran etexilate—Gastrointestinal disorder—Acetazolamide—glaucoma	0.0011	0.00141	CcSEcCtD
Dabigatran etexilate—Fatigue—Acetazolamide—glaucoma	0.0011	0.00141	CcSEcCtD
Dabigatran etexilate—Infection—Pilocarpine—glaucoma	0.0011	0.00141	CcSEcCtD
Dabigatran etexilate—Nausea—Methazolamide—glaucoma	0.0011	0.00141	CcSEcCtD
Dabigatran etexilate—Hypotension—Dorzolamide—glaucoma	0.0011	0.0014	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Brimonidine—glaucoma	0.00109	0.0014	CcSEcCtD
Dabigatran etexilate—Hypotension—Travoprost—glaucoma	0.00109	0.0014	CcSEcCtD
Dabigatran etexilate—Shock—Pilocarpine—glaucoma	0.00109	0.0014	CcSEcCtD
Dabigatran etexilate—Bronchospasm—Timolol—glaucoma	0.00109	0.00139	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Pilocarpine—glaucoma	0.00108	0.00139	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Brimonidine—glaucoma	0.00108	0.00138	CcSEcCtD
Dabigatran etexilate—Angina pectoris—Timolol—glaucoma	0.00108	0.00138	CcSEcCtD
Dabigatran etexilate—Hypotension—Brinzolamide—glaucoma	0.00108	0.00138	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Dorzolamide—glaucoma	0.00107	0.00137	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Travoprost—glaucoma	0.00106	0.00136	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Brimonidine—glaucoma	0.00106	0.00136	CcSEcCtD
Dabigatran etexilate—Fatigue—Brimonidine—glaucoma	0.00106	0.00136	CcSEcCtD
Dabigatran etexilate—F2—Angiopoietin receptor Tie2-mediated signaling—MMP2—glaucoma	0.00106	0.00483	CbGpPWpGaD
Dabigatran etexilate—Hypersensitivity—Apraclonidine—glaucoma	0.00105	0.00135	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Brinzolamide—glaucoma	0.00105	0.00135	CcSEcCtD
Dabigatran etexilate—UGT1A9—NRF2 pathway—TXN—glaucoma	0.00105	0.00478	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—PITX2—glaucoma	0.00105	0.00477	CbGpPWpGaD
Dabigatran etexilate—Dyspnoea—Dorzolamide—glaucoma	0.00105	0.00134	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Travoprost—glaucoma	0.00104	0.00133	CcSEcCtD
Dabigatran etexilate—Hypotension—Pilocarpine—glaucoma	0.00104	0.00133	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Dorzolamide—glaucoma	0.00103	0.00132	CcSEcCtD
Dabigatran etexilate—CES1—E2F transcription factor network—CDKN1B—glaucoma	0.00103	0.0047	CbGpPWpGaD
Dabigatran etexilate—Upper respiratory tract infection—Timolol—glaucoma	0.00103	0.00132	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Brinzolamide—glaucoma	0.00103	0.00132	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Travoprost—glaucoma	0.00103	0.00132	CcSEcCtD
Dabigatran etexilate—Asthenia—Apraclonidine—glaucoma	0.00103	0.00131	CcSEcCtD
Dabigatran etexilate—Urticaria—Acetazolamide—glaucoma	0.00102	0.0013	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Brinzolamide—glaucoma	0.00101	0.0013	CcSEcCtD
Dabigatran etexilate—Pruritus—Apraclonidine—glaucoma	0.00101	0.0013	CcSEcCtD
Dabigatran etexilate—Fatigue—Dorzolamide—glaucoma	0.00101	0.0013	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Pilocarpine—glaucoma	0.00101	0.00129	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Travoprost—glaucoma	0.00101	0.00129	CcSEcCtD
Dabigatran etexilate—Fatigue—Travoprost—glaucoma	0.00101	0.00129	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Betaxolol—glaucoma	0.00101	0.00129	CcSEcCtD
Dabigatran etexilate—Constipation—Travoprost—glaucoma	0.000999	0.00128	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Brinzolamide—glaucoma	0.000995	0.00127	CcSEcCtD
Dabigatran etexilate—Asthenia—Bimatoprost—glaucoma	0.000995	0.00127	CcSEcCtD
Dabigatran etexilate—Fatigue—Brinzolamide—glaucoma	0.000994	0.00127	CcSEcCtD
Dabigatran etexilate—F2—Angiopoietin receptor Tie2-mediated signaling—NOS3—glaucoma	0.000991	0.00452	CbGpPWpGaD
Dabigatran etexilate—Angioedema—Clonidine—glaucoma	0.000991	0.00127	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Pilocarpine—glaucoma	0.000988	0.00127	CcSEcCtD
Dabigatran etexilate—Angiopathy—Betaxolol—glaucoma	0.000984	0.00126	CcSEcCtD
Dabigatran etexilate—Pruritus—Bimatoprost—glaucoma	0.000981	0.00126	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Betaxolol—glaucoma	0.000979	0.00125	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Apraclonidine—glaucoma	0.000979	0.00125	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Betaxolol—glaucoma	0.000977	0.00125	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Pilocarpine—glaucoma	0.000975	0.00125	CcSEcCtD
Dabigatran etexilate—Syncope—Clonidine—glaucoma	0.000972	0.00125	CcSEcCtD
Dabigatran etexilate—F2—Metabolism of proteins—DHPS—glaucoma	0.000968	0.00442	CbGpPWpGaD
Dabigatran etexilate—Gastrointestinal pain—Dorzolamide—glaucoma	0.000959	0.00123	CcSEcCtD
Dabigatran etexilate—Palpitations—Clonidine—glaucoma	0.000958	0.00123	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Pilocarpine—glaucoma	0.000957	0.00123	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Travoprost—glaucoma	0.000955	0.00122	CcSEcCtD
Dabigatran etexilate—F2—GPCR ligand binding—OPN4—glaucoma	0.000954	0.00435	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Phase II conjugation—GSTM1—glaucoma	0.000954	0.00435	CbGpPWpGaD
Dabigatran etexilate—Loss of consciousness—Clonidine—glaucoma	0.000953	0.00122	CcSEcCtD
Dabigatran etexilate—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCA1—glaucoma	0.000952	0.00434	CbGpPWpGaD
Dabigatran etexilate—Constipation—Pilocarpine—glaucoma	0.000948	0.00121	CcSEcCtD
Dabigatran etexilate—Cough—Clonidine—glaucoma	0.000946	0.00121	CcSEcCtD
Dabigatran etexilate—Dizziness—Apraclonidine—glaucoma	0.000946	0.00121	CcSEcCtD
Dabigatran etexilate—Malnutrition—Betaxolol—glaucoma	0.000944	0.00121	CcSEcCtD
Dabigatran etexilate—UGT2B7—NRF2 pathway—TGFB2—glaucoma	0.000936	0.00427	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—NRF2 pathway—SLC6A1—glaucoma	0.000933	0.00426	CbGpPWpGaD
Dabigatran etexilate—Urticaria—Dorzolamide—glaucoma	0.000932	0.00119	CcSEcCtD
Dabigatran etexilate—Epistaxis—Timolol—glaucoma	0.000931	0.00119	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Dorzolamide—glaucoma	0.000927	0.00119	CcSEcCtD
Dabigatran etexilate—Sinusitis—Timolol—glaucoma	0.000926	0.00119	CcSEcCtD
Dabigatran etexilate—Chest pain—Clonidine—glaucoma	0.000923	0.00118	CcSEcCtD
Dabigatran etexilate—Arthralgia—Clonidine—glaucoma	0.000923	0.00118	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Travoprost—glaucoma	0.000923	0.00118	CcSEcCtD
Dabigatran etexilate—Asthenia—Acetazolamide—glaucoma	0.000918	0.00118	CcSEcCtD
Dabigatran etexilate—Dizziness—Bimatoprost—glaucoma	0.000917	0.00117	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Clonidine—glaucoma	0.000917	0.00117	CcSEcCtD
Dabigatran etexilate—Urticaria—Brinzolamide—glaucoma	0.000916	0.00117	CcSEcCtD
Dabigatran etexilate—Vomiting—Apraclonidine—glaucoma	0.000909	0.00116	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Pilocarpine—glaucoma	0.000906	0.00116	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Brimonidine—glaucoma	0.000905	0.00116	CcSEcCtD
Dabigatran etexilate—F2—Selenium Micronutrient Network—MTHFR—glaucoma	0.000904	0.00412	CbGpPWpGaD
Dabigatran etexilate—Dermatitis—Apraclonidine—glaucoma	0.000901	0.00115	CcSEcCtD
Dabigatran etexilate—Headache—Apraclonidine—glaucoma	0.000896	0.00115	CcSEcCtD
Dabigatran etexilate—Asthenia—Brimonidine—glaucoma	0.000881	0.00113	CcSEcCtD
Dabigatran etexilate—Infection—Clonidine—glaucoma	0.000879	0.00113	CcSEcCtD
Dabigatran etexilate—UGT2B7—Biological oxidations—GSTT1—glaucoma	0.000876	0.004	CbGpPWpGaD
Dabigatran etexilate—Abdominal pain—Pilocarpine—glaucoma	0.000876	0.00112	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Acetazolamide—glaucoma	0.000875	0.00112	CcSEcCtD
Dabigatran etexilate—Rash—Bimatoprost—glaucoma	0.000874	0.00112	CcSEcCtD
Dabigatran etexilate—Dermatitis—Bimatoprost—glaucoma	0.000874	0.00112	CcSEcCtD
Dabigatran etexilate—Oedema peripheral—Timolol—glaucoma	0.000873	0.00112	CcSEcCtD
Dabigatran etexilate—Anaemia—Betaxolol—glaucoma	0.000873	0.00112	CcSEcCtD
Dabigatran etexilate—Shock—Clonidine—glaucoma	0.000871	0.00112	CcSEcCtD
Dabigatran etexilate—Connective tissue disorder—Timolol—glaucoma	0.000871	0.00112	CcSEcCtD
Dabigatran etexilate—Pruritus—Brimonidine—glaucoma	0.000869	0.00111	CcSEcCtD
Dabigatran etexilate—Headache—Bimatoprost—glaucoma	0.000869	0.00111	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Clonidine—glaucoma	0.000868	0.00111	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Clonidine—glaucoma	0.000866	0.00111	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Dorzolamide—glaucoma	0.000864	0.00111	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Travoprost—glaucoma	0.00086	0.0011	CcSEcCtD
Dabigatran etexilate—Skin disorder—Clonidine—glaucoma	0.00086	0.0011	CcSEcCtD
Dabigatran etexilate—F2—GPCR ligand binding—PTGFR—glaucoma	0.000859	0.00392	CbGpPWpGaD
Dabigatran etexilate—Nausea—Apraclonidine—glaucoma	0.00085	0.00109	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Brinzolamide—glaucoma	0.000849	0.00109	CcSEcCtD
Dabigatran etexilate—Syncope—Betaxolol—glaucoma	0.000847	0.00108	CcSEcCtD
Dabigatran etexilate—Dizziness—Acetazolamide—glaucoma	0.000846	0.00108	CcSEcCtD
Dabigatran etexilate—Asthenia—Dorzolamide—glaucoma	0.000841	0.00108	CcSEcCtD
Dabigatran etexilate—Asthenia—Travoprost—glaucoma	0.000838	0.00107	CcSEcCtD
Dabigatran etexilate—Palpitations—Betaxolol—glaucoma	0.000834	0.00107	CcSEcCtD
Dabigatran etexilate—Pruritus—Dorzolamide—glaucoma	0.00083	0.00106	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Betaxolol—glaucoma	0.00083	0.00106	CcSEcCtD
Dabigatran etexilate—Asthenia—Brinzolamide—glaucoma	0.000827	0.00106	CcSEcCtD
Dabigatran etexilate—Hypotension—Clonidine—glaucoma	0.000827	0.00106	CcSEcCtD
Dabigatran etexilate—Pruritus—Travoprost—glaucoma	0.000826	0.00106	CcSEcCtD
Dabigatran etexilate—Cough—Betaxolol—glaucoma	0.000824	0.00106	CcSEcCtD
Dabigatran etexilate—Nausea—Bimatoprost—glaucoma	0.000824	0.00106	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Timolol—glaucoma	0.000822	0.00105	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Pilocarpine—glaucoma	0.000816	0.00105	CcSEcCtD
Dabigatran etexilate—Pruritus—Brinzolamide—glaucoma	0.000816	0.00104	CcSEcCtD
Dabigatran etexilate—Vomiting—Acetazolamide—glaucoma	0.000813	0.00104	CcSEcCtD
Dabigatran etexilate—Dizziness—Brimonidine—glaucoma	0.000812	0.00104	CcSEcCtD
Dabigatran etexilate—UGT1A9—PPARA activates gene expression—ABCA1—glaucoma	0.000811	0.0037	CbGpPWpGaD
Dabigatran etexilate—Musculoskeletal discomfort—Clonidine—glaucoma	0.000806	0.00103	CcSEcCtD
Dabigatran etexilate—Angiopathy—Timolol—glaucoma	0.000804	0.00103	CcSEcCtD
Dabigatran etexilate—Arthralgia—Betaxolol—glaucoma	0.000804	0.00103	CcSEcCtD
Dabigatran etexilate—Chest pain—Betaxolol—glaucoma	0.000804	0.00103	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Dorzolamide—glaucoma	0.000802	0.00103	CcSEcCtD
Dabigatran etexilate—Headache—Acetazolamide—glaucoma	0.000802	0.00103	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Timolol—glaucoma	0.0008	0.00102	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Travoprost—glaucoma	0.000799	0.00102	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Timolol—glaucoma	0.000798	0.00102	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Betaxolol—glaucoma	0.000798	0.00102	CcSEcCtD
Dabigatran etexilate—Asthenia—Pilocarpine—glaucoma	0.000795	0.00102	CcSEcCtD
Dabigatran etexilate—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—ABCA1—glaucoma	0.000794	0.00362	CbGpPWpGaD
Dabigatran etexilate—F2—Cell surface interactions at the vascular wall—MMP1—glaucoma	0.000792	0.00361	CbGpPWpGaD
Dabigatran etexilate—Dyspnoea—Clonidine—glaucoma	0.000789	0.00101	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Brinzolamide—glaucoma	0.000789	0.00101	CcSEcCtD
Dabigatran etexilate—Pruritus—Pilocarpine—glaucoma	0.000784	0.001	CcSEcCtD
Dabigatran etexilate—Dizziness—Dorzolamide—glaucoma	0.000775	0.000993	CcSEcCtD
Dabigatran etexilate—UGT1A9—Phase II conjugation—GSTM1—glaucoma	0.000775	0.00354	CbGpPWpGaD
Dabigatran etexilate—Rash—Brimonidine—glaucoma	0.000774	0.000992	CcSEcCtD
Dabigatran etexilate—Dermatitis—Brimonidine—glaucoma	0.000774	0.000991	CcSEcCtD
Dabigatran etexilate—Dizziness—Travoprost—glaucoma	0.000772	0.000989	CcSEcCtD
Dabigatran etexilate—Malnutrition—Timolol—glaucoma	0.000771	0.000988	CcSEcCtD
Dabigatran etexilate—Headache—Brimonidine—glaucoma	0.000769	0.000985	CcSEcCtD
Dabigatran etexilate—Infection—Betaxolol—glaucoma	0.000765	0.00098	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Clonidine—glaucoma	0.000764	0.000979	CcSEcCtD
Dabigatran etexilate—Fatigue—Clonidine—glaucoma	0.000763	0.000977	CcSEcCtD
Dabigatran etexilate—Dizziness—Brinzolamide—glaucoma	0.000762	0.000977	CcSEcCtD
Dabigatran etexilate—UGT1A9—NRF2 pathway—TGFB2—glaucoma	0.000761	0.00347	CbGpPWpGaD
Dabigatran etexilate—Nausea—Acetazolamide—glaucoma	0.00076	0.000973	CcSEcCtD
Dabigatran etexilate—F2—Cell surface interactions at the vascular wall—CAV1—glaucoma	0.000759	0.00346	CbGpPWpGaD
Dabigatran etexilate—Diarrhoea—Pilocarpine—glaucoma	0.000758	0.000971	CcSEcCtD
Dabigatran etexilate—Shock—Betaxolol—glaucoma	0.000758	0.000971	CcSEcCtD
Dabigatran etexilate—Constipation—Clonidine—glaucoma	0.000757	0.000969	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Betaxolol—glaucoma	0.000756	0.000968	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Betaxolol—glaucoma	0.000754	0.000966	CcSEcCtD
Dabigatran etexilate—Skin disorder—Betaxolol—glaucoma	0.000748	0.000959	CcSEcCtD
Dabigatran etexilate—Vomiting—Dorzolamide—glaucoma	0.000746	0.000955	CcSEcCtD
Dabigatran etexilate—Rash—Dorzolamide—glaucoma	0.000739	0.000947	CcSEcCtD
Dabigatran etexilate—Dermatitis—Dorzolamide—glaucoma	0.000739	0.000946	CcSEcCtD
Dabigatran etexilate—Rash—Travoprost—glaucoma	0.000736	0.000943	CcSEcCtD
Dabigatran etexilate—Dermatitis—Travoprost—glaucoma	0.000736	0.000942	CcSEcCtD
Dabigatran etexilate—Headache—Dorzolamide—glaucoma	0.000735	0.000941	CcSEcCtD
Dabigatran etexilate—Vomiting—Brinzolamide—glaucoma	0.000733	0.000939	CcSEcCtD
Dabigatran etexilate—Dizziness—Pilocarpine—glaucoma	0.000733	0.000939	CcSEcCtD
Dabigatran etexilate—Headache—Travoprost—glaucoma	0.000732	0.000937	CcSEcCtD
Dabigatran etexilate—Nausea—Brimonidine—glaucoma	0.000729	0.000934	CcSEcCtD
Dabigatran etexilate—Rash—Brinzolamide—glaucoma	0.000727	0.000931	CcSEcCtD
Dabigatran etexilate—Dermatitis—Brinzolamide—glaucoma	0.000726	0.00093	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Clonidine—glaucoma	0.000724	0.000927	CcSEcCtD
Dabigatran etexilate—F2—Cell surface interactions at the vascular wall—FN1—glaucoma	0.000723	0.0033	CbGpPWpGaD
Dabigatran etexilate—Headache—Brinzolamide—glaucoma	0.000722	0.000925	CcSEcCtD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—TGFB2—glaucoma	0.000721	0.00329	CbGpPWpGaD
Dabigatran etexilate—Hypotension—Betaxolol—glaucoma	0.00072	0.000922	CcSEcCtD
Dabigatran etexilate—UGT1A9—Biological oxidations—GSTT1—glaucoma	0.000712	0.00325	CbGpPWpGaD
Dabigatran etexilate—Angioedema—Timolol—glaucoma	0.000705	0.000903	CcSEcCtD
Dabigatran etexilate—Vomiting—Pilocarpine—glaucoma	0.000705	0.000902	CcSEcCtD
Dabigatran etexilate—Urticaria—Clonidine—glaucoma	0.000703	0.0009	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Betaxolol—glaucoma	0.000702	0.000899	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Clonidine—glaucoma	0.0007	0.000896	CcSEcCtD
Dabigatran etexilate—Rash—Pilocarpine—glaucoma	0.000699	0.000895	CcSEcCtD
Dabigatran etexilate—UGT2B7—Biological oxidations—CYP1B1—glaucoma	0.000698	0.00318	CbGpPWpGaD
Dabigatran etexilate—Dermatitis—Pilocarpine—glaucoma	0.000698	0.000894	CcSEcCtD
Dabigatran etexilate—Nausea—Dorzolamide—glaucoma	0.000697	0.000892	CcSEcCtD
Dabigatran etexilate—UGT1A9—Aryl Hydrocarbon Receptor Pathway—CDKN1B—glaucoma	0.000696	0.00317	CbGpPWpGaD
Dabigatran etexilate—Headache—Pilocarpine—glaucoma	0.000694	0.000889	CcSEcCtD
Dabigatran etexilate—Nausea—Travoprost—glaucoma	0.000694	0.000888	CcSEcCtD
Dabigatran etexilate—Syncope—Timolol—glaucoma	0.000692	0.000886	CcSEcCtD
Dabigatran etexilate—UGT2B7—Metapathway biotransformation—CYP1B1—glaucoma	0.000689	0.00314	CbGpPWpGaD
Dabigatran etexilate—Dyspnoea—Betaxolol—glaucoma	0.000687	0.00088	CcSEcCtD
Dabigatran etexilate—Nausea—Brinzolamide—glaucoma	0.000685	0.000877	CcSEcCtD
Dabigatran etexilate—Palpitations—Timolol—glaucoma	0.000682	0.000873	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Betaxolol—glaucoma	0.000678	0.000869	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Timolol—glaucoma	0.000678	0.000868	CcSEcCtD
Dabigatran etexilate—Cough—Timolol—glaucoma	0.000673	0.000862	CcSEcCtD
Dabigatran etexilate—Hypertension—Timolol—glaucoma	0.000666	0.000853	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Betaxolol—glaucoma	0.000665	0.000852	CcSEcCtD
Dabigatran etexilate—Fatigue—Betaxolol—glaucoma	0.000664	0.000851	CcSEcCtD
Dabigatran etexilate—Constipation—Betaxolol—glaucoma	0.000659	0.000844	CcSEcCtD
Dabigatran etexilate—UGT2B15—Metabolism—CA1—glaucoma	0.000659	0.003	CbGpPWpGaD
Dabigatran etexilate—Nausea—Pilocarpine—glaucoma	0.000658	0.000843	CcSEcCtD
Dabigatran etexilate—Chest pain—Timolol—glaucoma	0.000657	0.000841	CcSEcCtD
Dabigatran etexilate—Arthralgia—Timolol—glaucoma	0.000657	0.000841	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Timolol—glaucoma	0.000652	0.000835	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Clonidine—glaucoma	0.000652	0.000835	CcSEcCtD
Dabigatran etexilate—UGT2B15—Metabolism—CTSA—glaucoma	0.000638	0.00291	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—NRF2 pathway—GSTM1—glaucoma	0.000636	0.0029	CbGpPWpGaD
Dabigatran etexilate—Asthenia—Clonidine—glaucoma	0.000635	0.000813	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Timolol—glaucoma	0.000629	0.000806	CcSEcCtD
Dabigatran etexilate—Pruritus—Clonidine—glaucoma	0.000626	0.000802	CcSEcCtD
Dabigatran etexilate—Infection—Timolol—glaucoma	0.000625	0.000801	CcSEcCtD
Dabigatran etexilate—Shock—Timolol—glaucoma	0.000619	0.000793	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Timolol—glaucoma	0.000617	0.000791	CcSEcCtD
Dabigatran etexilate—UGT2B7—Metabolism—NARFL—glaucoma	0.000614	0.0028	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CA5A—glaucoma	0.000614	0.0028	CbGpPWpGaD
Dabigatran etexilate—F2—Angiopoietin receptor Tie2-mediated signaling—TNF—glaucoma	0.000612	0.00279	CbGpPWpGaD
Dabigatran etexilate—Urticaria—Betaxolol—glaucoma	0.000612	0.000784	CcSEcCtD
Dabigatran etexilate—Skin disorder—Timolol—glaucoma	0.000611	0.000783	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Clonidine—glaucoma	0.000605	0.000776	CcSEcCtD
Dabigatran etexilate—F2—Metabolism of proteins—CTSA—glaucoma	0.000604	0.00276	CbGpPWpGaD
Dabigatran etexilate—F2—Vitamin B12 Metabolism—TNF—glaucoma	0.000603	0.00275	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—CA2—glaucoma	0.000602	0.00275	CbGpPWpGaD
Dabigatran etexilate—Hypotension—Timolol—glaucoma	0.000588	0.000753	CcSEcCtD
Dabigatran etexilate—Dizziness—Clonidine—glaucoma	0.000585	0.00075	CcSEcCtD
Dabigatran etexilate—F2—Selenium Micronutrient Network—PTGS2—glaucoma	0.000577	0.00263	CbGpPWpGaD
Dabigatran etexilate—Musculoskeletal discomfort—Timolol—glaucoma	0.000573	0.000734	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Betaxolol—glaucoma	0.000568	0.000727	CcSEcCtD
Dabigatran etexilate—UGT1A9—Biological oxidations—CYP1B1—glaucoma	0.000567	0.00259	CbGpPWpGaD
Dabigatran etexilate—F2—G alpha (q) signalling events—EDN1—glaucoma	0.000566	0.00258	CbGpPWpGaD
Dabigatran etexilate—Vomiting—Clonidine—glaucoma	0.000563	0.000721	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Timolol—glaucoma	0.000561	0.000719	CcSEcCtD
Dabigatran etexilate—UGT1A9—Metapathway biotransformation—CYP1B1—glaucoma	0.00056	0.00255	CbGpPWpGaD
Dabigatran etexilate—F2—Peptide ligand-binding receptors—EDN1—glaucoma	0.000559	0.00255	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Biological oxidations—GSTM1—glaucoma	0.000558	0.00255	CbGpPWpGaD
Dabigatran etexilate—Rash—Clonidine—glaucoma	0.000558	0.000715	CcSEcCtD
Dabigatran etexilate—Dermatitis—Clonidine—glaucoma	0.000557	0.000714	CcSEcCtD
Dabigatran etexilate—F2—Metabolism of proteins—ACE2—glaucoma	0.000556	0.00254	CbGpPWpGaD
Dabigatran etexilate—Headache—Clonidine—glaucoma	0.000554	0.00071	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Timolol—glaucoma	0.000554	0.00071	CcSEcCtD
Dabigatran etexilate—Asthenia—Betaxolol—glaucoma	0.000553	0.000708	CcSEcCtD
Dabigatran etexilate—UGT2B7—Metapathway biotransformation—GSTM1—glaucoma	0.000551	0.00251	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—ABCA1—glaucoma	0.000547	0.0025	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—SOD1—glaucoma	0.000546	0.00249	CbGpPWpGaD
Dabigatran etexilate—Pruritus—Betaxolol—glaucoma	0.000545	0.000698	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Timolol—glaucoma	0.000543	0.000696	CcSEcCtD
Dabigatran etexilate—Fatigue—Timolol—glaucoma	0.000543	0.000695	CcSEcCtD
Dabigatran etexilate—F2—GPCR downstream signaling—OPN4—glaucoma	0.000539	0.00246	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—CTSA—glaucoma	0.00053	0.00242	CbGpPWpGaD
Dabigatran etexilate—Diarrhoea—Betaxolol—glaucoma	0.000527	0.000675	CcSEcCtD
Dabigatran etexilate—Nausea—Clonidine—glaucoma	0.000526	0.000673	CcSEcCtD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—FN1—glaucoma	0.000521	0.00238	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—NRF2 pathway—GSTM1—glaucoma	0.000517	0.00236	CbGpPWpGaD
Dabigatran etexilate—Gastrointestinal pain—Timolol—glaucoma	0.000515	0.000659	CcSEcCtD
Dabigatran etexilate—Dizziness—Betaxolol—glaucoma	0.000509	0.000653	CcSEcCtD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—glaucoma	0.000507	0.00231	CbGpPWpGaD
Dabigatran etexilate—Urticaria—Timolol—glaucoma	0.0005	0.00064	CcSEcCtD
Dabigatran etexilate—UGT1A9—Metabolism—CA5A—glaucoma	0.000499	0.00228	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—NARFL—glaucoma	0.000499	0.00228	CbGpPWpGaD
Dabigatran etexilate—Abdominal pain—Timolol—glaucoma	0.000498	0.000637	CcSEcCtD
Dabigatran etexilate—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TNF—glaucoma	0.000496	0.00226	CbGpPWpGaD
Dabigatran etexilate—F2—Folate Metabolism—TNF—glaucoma	0.00049	0.00224	CbGpPWpGaD
Dabigatran etexilate—Vomiting—Betaxolol—glaucoma	0.00049	0.000627	CcSEcCtD
Dabigatran etexilate—F2—Signaling by GPCR—OPN4—glaucoma	0.00049	0.00223	CbGpPWpGaD
Dabigatran etexilate—F2—Peptide ligand-binding receptors—C3—glaucoma	0.000489	0.00223	CbGpPWpGaD
Dabigatran etexilate—Rash—Betaxolol—glaucoma	0.000486	0.000622	CcSEcCtD
Dabigatran etexilate—F2—GPCR downstream signaling—PTGFR—glaucoma	0.000486	0.00221	CbGpPWpGaD
Dabigatran etexilate—Dermatitis—Betaxolol—glaucoma	0.000485	0.000622	CcSEcCtD
Dabigatran etexilate—Headache—Betaxolol—glaucoma	0.000483	0.000618	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Timolol—glaucoma	0.000464	0.000594	CcSEcCtD
Dabigatran etexilate—Nausea—Betaxolol—glaucoma	0.000458	0.000586	CcSEcCtD
Dabigatran etexilate—UGT1A9—Biological oxidations—GSTM1—glaucoma	0.000454	0.00207	CbGpPWpGaD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—EDN1—glaucoma	0.000453	0.00207	CbGpPWpGaD
Dabigatran etexilate—Asthenia—Timolol—glaucoma	0.000452	0.000578	CcSEcCtD
Dabigatran etexilate—UGT1A9—Metapathway biotransformation—GSTM1—glaucoma	0.000447	0.00204	CbGpPWpGaD
Dabigatran etexilate—Pruritus—Timolol—glaucoma	0.000445	0.00057	CcSEcCtD
Dabigatran etexilate—F2—Signaling by GPCR—PTGFR—glaucoma	0.000441	0.00201	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—SMO—glaucoma	0.000433	0.00198	CbGpPWpGaD
Dabigatran etexilate—F2—Folate Metabolism—TP53—glaucoma	0.000432	0.00197	CbGpPWpGaD
Dabigatran etexilate—Diarrhoea—Timolol—glaucoma	0.000431	0.000552	CcSEcCtD
Dabigatran etexilate—UGT2B15—Metabolism—TXN—glaucoma	0.000424	0.00194	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—LRP12—glaucoma	0.000417	0.0019	CbGpPWpGaD
Dabigatran etexilate—Dizziness—Timolol—glaucoma	0.000416	0.000533	CcSEcCtD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—PEX19—glaucoma	0.000416	0.0019	CbGpPWpGaD
Dabigatran etexilate—Vomiting—Timolol—glaucoma	0.0004	0.000513	CcSEcCtD
Dabigatran etexilate—Rash—Timolol—glaucoma	0.000397	0.000508	CcSEcCtD
Dabigatran etexilate—Dermatitis—Timolol—glaucoma	0.000396	0.000508	CcSEcCtD
Dabigatran etexilate—Headache—Timolol—glaucoma	0.000394	0.000505	CcSEcCtD
Dabigatran etexilate—ABCB1—Allograft Rejection—IL1A—glaucoma	0.00039	0.00178	CbGpPWpGaD
Dabigatran etexilate—F2—Selenium Micronutrient Network—TNF—glaucoma	0.000389	0.00178	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—FN1—glaucoma	0.00038	0.00173	CbGpPWpGaD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—EDN1—glaucoma	0.000375	0.00171	CbGpPWpGaD
Dabigatran etexilate—Nausea—Timolol—glaucoma	0.000374	0.000479	CcSEcCtD
Dabigatran etexilate—F2—Hemostasis—TGFB2—glaucoma	0.000371	0.00169	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—FAS—glaucoma	0.000348	0.00159	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—C3—glaucoma	0.000343	0.00156	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—GSTT1—glaucoma	0.000329	0.0015	CbGpPWpGaD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—C3—glaucoma	0.000328	0.00149	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—glaucoma	0.000303	0.00138	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CA1—glaucoma	0.0003	0.00137	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—PAX6—glaucoma	0.000297	0.00135	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—glaucoma	0.000294	0.00134	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CTSA—glaucoma	0.000291	0.00132	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—OPN4—glaucoma	0.000289	0.00132	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—EDN1—glaucoma	0.000286	0.0013	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—SOD1—glaucoma	0.000282	0.00128	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—SLC4A4—glaucoma	0.000281	0.00128	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CA2—glaucoma	0.000274	0.00125	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—HEYL—glaucoma	0.000269	0.00123	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—CYP1B1—glaucoma	0.000262	0.0012	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—ABCA1—glaucoma	0.000262	0.0012	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PTGFR—glaucoma	0.00026	0.00119	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—C3—glaucoma	0.00025	0.00114	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CA1—glaucoma	0.000244	0.00111	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CTSA—glaucoma	0.000236	0.00108	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CA5A—glaucoma	0.000229	0.00104	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—NARFL—glaucoma	0.000229	0.00104	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CA2—glaucoma	0.000223	0.00102	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—SMO—glaucoma	0.000222	0.00101	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—NTRK1—glaucoma	0.000219	0.000998	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	0.000218	0.000994	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	0.000218	0.000994	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—VEGFA—glaucoma	0.000218	0.000992	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—MMP1—glaucoma	0.000215	0.000979	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—GSTM1—glaucoma	0.00021	0.000956	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—CAV1—glaucoma	0.000206	0.000939	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—RPTOR—glaucoma	0.000204	0.00093	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN2B—glaucoma	0.000202	0.00092	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—glaucoma	0.0002	0.000914	CbGpPWpGaD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—VEGFA—glaucoma	0.000199	0.000907	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NCK2—glaucoma	0.000197	0.0009	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—FN1—glaucoma	0.000196	0.000893	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—TXN—glaucoma	0.000193	0.000882	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—SLC6A13—glaucoma	0.000187	0.000854	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—MTHFR—glaucoma	0.000185	0.000845	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—APOE—glaucoma	0.000172	0.000787	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—VEGFA—glaucoma	0.000172	0.000785	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—glaucoma	0.000172	0.000782	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—CAV1—glaucoma	0.000171	0.000779	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—MMP1—glaucoma	0.000169	0.00077	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—HDAC9—glaucoma	0.000168	0.000765	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—EDN1—glaucoma	0.000161	0.000736	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—TXN—glaucoma	0.000157	0.000716	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—NOS3—glaucoma	0.000156	0.00071	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—GSTT1—glaucoma	0.00015	0.000684	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—TNF—glaucoma	0.000148	0.000673	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—BAD—glaucoma	0.000147	0.000669	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—EDN1—glaucoma	0.000147	0.000669	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—APOE—glaucoma	0.000143	0.000654	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—CAV1—glaucoma	0.000142	0.000648	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—C3—glaucoma	0.000141	0.000643	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—SLC6A1—glaucoma	0.000137	0.000625	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—SMO—glaucoma	0.000131	0.000599	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—MMP2—glaucoma	0.000131	0.000596	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—NOS3—glaucoma	0.000129	0.000589	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—C3—glaucoma	0.000128	0.000584	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—GSTT1—glaucoma	0.000122	0.000555	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NTRK2—glaucoma	0.00012	0.000548	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CYP1B1—glaucoma	0.000119	0.000545	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—ABCA1—glaucoma	0.000119	0.000545	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PTGS2—glaucoma	0.000118	0.000539	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—VEGFA—glaucoma	0.000112	0.000511	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CA1—glaucoma	0.000112	0.00051	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CTSA—glaucoma	0.000108	0.000494	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—glaucoma	0.000108	0.000492	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NGFR—glaucoma	0.000103	0.00047	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CA2—glaucoma	0.000102	0.000466	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—glaucoma	0.000102	0.000466	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	9.82e-05	0.000448	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NTRK1—glaucoma	9.79e-05	0.000447	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CYP1B1—glaucoma	9.7e-05	0.000443	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ABCA1—glaucoma	9.7e-05	0.000443	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—GSTM1—glaucoma	9.55e-05	0.000435	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CDKN2B—glaucoma	9.02e-05	0.000412	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—EDN1—glaucoma	8.66e-05	0.000395	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—glaucoma	8.5e-05	0.000388	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—TP53—glaucoma	8.47e-05	0.000386	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—MTHFR—glaucoma	8.44e-05	0.000385	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NGF—glaucoma	7.96e-05	0.000363	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—APOE—glaucoma	7.86e-05	0.000358	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CAV1—glaucoma	7.78e-05	0.000355	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—GSTM1—glaucoma	7.76e-05	0.000354	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—C3—glaucoma	7.56e-05	0.000345	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—glaucoma	7.28e-05	0.000332	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—TXN—glaucoma	7.21e-05	0.000329	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—APOE—glaucoma	7.04e-05	0.000321	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CAV1—glaucoma	6.98e-05	0.000318	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—MTHFR—glaucoma	6.86e-05	0.000313	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—FN1—glaucoma	6.64e-05	0.000303	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—BAD—glaucoma	6.56e-05	0.000299	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—glaucoma	6.42e-05	0.000293	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—APOE—glaucoma	6.38e-05	0.000291	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CAV1—glaucoma	6.32e-05	0.000288	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—NOS3—glaucoma	5.88e-05	0.000268	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GSTT1—glaucoma	5.59e-05	0.000255	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PTGS2—glaucoma	5.38e-05	0.000245	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NOS3—glaucoma	5.28e-05	0.000241	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—NOS3—glaucoma	4.78e-05	0.000218	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CDKN1B—glaucoma	4.57e-05	0.000208	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CYP1B1—glaucoma	4.45e-05	0.000203	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ABCA1—glaucoma	4.45e-05	0.000203	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PTGS2—glaucoma	4.37e-05	0.000199	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MMP9—glaucoma	4.23e-05	0.000193	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—VEGFA—glaucoma	3.8e-05	0.000173	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GSTM1—glaucoma	3.56e-05	0.000162	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—MTHFR—glaucoma	3.15e-05	0.000143	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—APOE—glaucoma	2.93e-05	0.000134	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CAV1—glaucoma	2.9e-05	0.000132	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TP53—glaucoma	2.87e-05	0.000131	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—NOS3—glaucoma	2.19e-05	0.0001	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PTGS2—glaucoma	2.01e-05	9.15e-05	CbGpPWpGaD
